Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Harvard Bioscience Inc (NASDAQ: HBIO) closed the day trading at $0.58 up 2.60% from the previous closing price of $0.56. In other words, the price has increased by $2.60 from its previous closing price. On the day, 0.59 million shares were traded. HBIO stock price reached its highest trading level at $0.6 during the session, while it also had its lowest trading level at $0.5623.
Ratios:
For a better understanding of HBIO, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.79 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 3.83. For the most recent quarter (mrq), Quick Ratio is recorded 0.41 and its Current Ratio is at 0.81. In the meantime, Its Debt-to-Equity ratio is 3.04 whereas as Long-Term Debt/Eq ratio is at 0.52.
On March 10, 2023, The Benchmark Company Upgraded its rating to Buy which previously was Speculative Buy and also upped its target price recommendation from $3 to $4.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HBIO now has a Market Capitalization of 25842830 and an Enterprise Value of 61810832. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.07. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.30 while its Price-to-Book (P/B) ratio in mrq is 1.84. Its current Enterprise Value per Revenue stands at 0.707 whereas that against EBITDA is 12.394.
Stock Price History:
The Beta on a monthly basis for HBIO is 1.55, which has changed by -0.7046632 over the last 52 weeks, in comparison to a change of 0.15507638 over the same period for the S&P500. Over the past 52 weeks, HBIO has reached a high of $2.07, while it has fallen to a 52-week low of $0.28. The 50-Day Moving Average of the stock is -14.05%, while the 200-Day Moving Average is calculated to be 15.30%.
Shares Statistics:
Over the past 3-months, HBIO traded about 6.41M shares per day on average, while over the past 10 days, HBIO traded about 313420 shares per day. A total of 44.58M shares are outstanding, with a floating share count of 38.25M. Insiders hold about 14.19% of the company’s shares, while institutions hold 36.00% stake in the company. Shares short for HBIO as of 1767139200 were 445314 with a Short Ratio of 0.07, compared to 1764288000 on 477324. Therefore, it implies a Short% of Shares Outstanding of 445314 and a Short% of Float of 1.08.
Earnings Estimates
The stock of Harvard Bioscience Inc (HBIO) is currently drawing attention from 2.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.0, with high estimates of $0.01 and low estimates of -$0.02.
Analysts are recommending an EPS of between $0.04 and $0.02 for the fiscal current year, implying an average EPS of $0.03. EPS for the following year is $0.09, with 2.0 analysts recommending between $0.13 and $0.06.
Revenue Estimates
2 analysts predict $23.1M in revenue. The current quarter. It ranges from a high estimate of $23.4M to a low estimate of $22.8M. As of. The current estimate, Harvard Bioscience Inc’s year-ago sales were $24.56MFor the next quarter, 2 analysts are estimating revenue of $21.25M. There is a high estimate of $21.7M for the next quarter, whereas the lowest estimate is $20.8M.
A total of 2 analysts have provided revenue estimates for HBIO’s current fiscal year. The highest revenue estimate was $86.2M, while the lowest revenue estimate was $85.6M, resulting in an average revenue estimate of $85.9M. In the same quarter a year ago, actual revenue was $94.14MBased on 2 analysts’ estimates, the company’s revenue will be $92.6M in the next fiscal year. The high estimate is $95.6M and the low estimate is $89.6M.
